Grifols, S.A. American Depositary Receipt (GRFS)
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?
On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.
Grifols Stock Declines After Brookfield Drops Buyout Offer
Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.
Grifols shares tumble after report on Brookfield abandoning takeover plan
Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm.
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Grifols: Brookfields potential $6.8 bln offer undervalues the firm
Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential.
Grifols on track to meet 2024 targets despite third-quarter profit drop
Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down
Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage.
Grifols plans to invest $402 million in new industrial centre, El Economista says
Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citing unidentified company sources.
The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.
Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.
The Schall Law Firm Is Looking Into Grifols SA For Possibly Violating Securities Laws And Stakeholders Are Invited To Partake In The Investigation
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.
Grifols SA May Have Committed Securities Fraud And Investors With Losses Should Join The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.
